ABIO
ARCA biopharma, Inc. [ABIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABIO Stock Summary
Top 10 Correlated ETFs
ABIO
Top 10 Correlated Stocks
ABIO
In the News
ABIO Financial details
Company Rating
Neutral
Market Cap
46.84M
Income
-4.37M
Revenue
0
Book val./share
2.55
Cash/share
2.58
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-5.94
Forward P/E
-
PEG
1.13
P/S
-
P/B
0.64
P/C
1.28
P/FCF
-4.44
Quick Ratio
38.8
Current Ratio
39.21
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.3
EPS next Y
-
EPS next Q
-
EPS this Y
-42.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-23.99%
-
-
-
-
SMA20
50%
SMA50
50%
SMA100
50%
Inst Own
0.01%
Inst Trans
0%
ROA
-10%
ROE
-10%
ROC
-0.19%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.56-3.88
52W High
+10.33%
52W Low
+231%
RSI
79
Rel Volume
0.57
Avg Volume
1.43M
Volume
815.8K
Perf Week
1.85%
Perf Month
101.83%
Perf Quarter
77.01%
Perf Half Y
62.25%
-
-
-
-
Beta
1.205
-
-
Volatility
0.04%, 0.73%
Prev Close
1.85%
Price
3.31
Change
3.76%
ABIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -4.15 | -2.07 | -1.38 | -0.64 | -0.37 | |
| Operating cash flow per share | -3.63 | -1.64 | -1.35 | -0.76 | -0.35 | |
| Free cash flow per share | -3.64 | -1.64 | -1.35 | -0.76 | -0.35 | |
| Cash per share | 6.33 | 10.42 | 3.84 | 2.95 | 2.6 | |
| Book value per share | 5.76 | 9.88 | 3.67 | 2.89 | 2.57 | |
| Tangible book value per share | 5.76 | 9.88 | 3.67 | 2.89 | 2.57 | |
| Share holders equity per share | 5.76 | 9.88 | 3.67 | 2.89 | 2.57 | |
| Interest debt per share | 0.02 | 0.1 | 0.03 | 0.07 | 0.02 | |
| Market cap | 7.54M | 18.89M | 29.89M | 34.15M | 24.51M | |
| Enterprise value | -793.75K | -29.77M | -23.08M | -8.01M | -12.64M | |
| P/E ratio | -1.38 | -1.94 | -1.55 | -3.69 | -4.59 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.57 | -2.45 | -1.59 | -3.13 | -4.89 | |
| PFCF ratio | -1.57 | -2.44 | -1.59 | -3.13 | -4.89 | |
| P/B Ratio | 0.99 | 0.41 | 0.59 | 0.82 | 0.66 | |
| PTB ratio | 0.99 | 0.41 | 0.59 | 0.82 | 0.66 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.14 | 3.06 | 1.19 | 0.76 | 1.73 | |
| EV to operating cash flow | 0.17 | 3.85 | 1.23 | 0.73 | 2.52 | |
| EV to free cash flow | 0.17 | 3.84 | 1.23 | 0.73 | 2.52 | |
| Earnings yield | -0.73 | -0.52 | -0.64 | -0.27 | -0.22 | |
| Free cash flow yield | -0.64 | -0.41 | -0.63 | -0.32 | -0.2 | |
| Debt to equity | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 1.5 | 5 | 2.74 | 3.98 | 5.09 | |
| Current ratio | 9.16 | 14.28 | 15.56 | 37.72 | 59.01 | |
| Interest coverage | -830.57 | -1.09K | 0 | -15.7 | 0 | |
| Income quality | 0.88 | 0.79 | 0.97 | 1.1 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.04 | -0.2 | -0.47 | -0.02 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 23.19 | 21.43 | 10.69 | 6.46 | 4.63 | |
| ROIC | -0.74 | -0.21 | -0.37 | -0.23 | -0.19 | |
| Return on tangible assets | -0.64 | -0.19 | -0.35 | -0.21 | -0.14 | |
| Graham Net | 5.63 | 9.59 | 3.56 | 2.85 | 2.54 | |
| Working capital | 7.55M | 46.47M | 50.92M | 41.57M | 36.96M | |
| Tangible asset value | 7.61M | 46.52M | 51.04M | 41.67M | 37.02M | |
| Net current asset value | 7.55M | 46.06M | 50.54M | 41.29M | 36.75M | |
| Invested capital | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 324K | 1.1M | 1.45M | 725.5K | 348K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.71K | 6.96K | 4.48K | 1.07K | 1.19K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.21 | 0.05 | 0.08 | 0.34 | 0.31 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.72 | -0.21 | -0.38 | -0.22 | -0.14 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.06 | -0.06 | -0.07 | -0.1 | -0.08 | |
| Operating cash flow per share | -0.1 | -0.11 | -0.05 | -0.12 | -0.07 | |
| Free cash flow per share | -0.1 | -0.11 | -0.05 | -0.12 | -0.07 | |
| Cash per share | 2.95 | 2.83 | 2.79 | 2.67 | 2.58 | |
| Book value per share | 2.89 | 2.81 | 2.72 | 2.63 | 2.55 | |
| Tangible book value per share | 2.89 | 2.81 | 2.72 | 2.63 | 2.55 | |
| Share holders equity per share | 2.89 | 2.81 | 2.72 | 2.63 | 2.55 | |
| Interest debt per share | 0.05 | -0.01 | 0.02 | 0.02 | 0.02 | |
| Market cap | 34.15M | 28.68M | 29.25M | 28.96M | 24.65M | |
| Enterprise value | -8.01M | -11.91M | -10.66M | -9.3M | -12.58M | |
| P/E ratio | -10.67 | -8 | -7.63 | -5.09 | -5.66 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -22.86 | -17.98 | -42.15 | -17.35 | -23.34 | |
| PFCF ratio | -22.86 | -17.98 | -42.15 | -17.35 | -23.34 | |
| P/B Ratio | 0.82 | 0.71 | 0.75 | 0.76 | 0.67 | |
| PTB ratio | 0.82 | 0.71 | 0.75 | 0.76 | 0.67 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 5.28 | 6.74 | 5.4 | 4.8 | 8.02 | |
| EV to operating cash flow | 5.36 | 7.47 | 15.36 | 5.57 | 11.91 | |
| EV to free cash flow | 5.36 | 7.47 | 15.36 | 5.57 | 11.91 | |
| Earnings yield | -0.02 | -0.03 | -0.03 | -0.05 | -0.04 | |
| Free cash flow yield | -0.04 | -0.06 | -0.02 | -0.06 | -0.04 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 27.76 | 22.97 | 20.23 | 19.75 | 23.76 | |
| Current ratio | 37.72 | 32.94 | 25.44 | 39.21 | 59.01 | |
| Interest coverage | -4.14 | 3.99 | 0 | 0 | 0 | |
| Income quality | 1.27 | 1.18 | 0.47 | 1.17 | 0.97 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.9 | 1.98 | 2.02 | 2.42 | 2.08 | |
| ROIC | -0.02 | -0.03 | -0.03 | -0.05 | -0.04 | |
| Return on tangible assets | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | |
| Graham Net | 2.85 | 2.73 | 2.66 | 2.59 | 2.52 | |
| Working capital | 41.57M | 40.44M | 39.15M | 37.9M | 36.96M | |
| Tangible asset value | 41.67M | 40.53M | 39.24M | 37.97M | 37.02M | |
| Net current asset value | 41.29M | 40.17M | 38.91M | 37.68M | 36.75M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 463.5K | 350K | 303.5K | 281.5K | 342K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.04K | 1.14K | 747.93 | 966 | 1.42K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.09 | 0.08 | 0.12 | 0.09 | 0.06 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.02 | -0.02 | -0.02 | -0.04 | -0.03 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ABIO Frequently Asked Questions
What is ARCA biopharma, Inc. stock symbol ?
ARCA biopharma, Inc. is a US stock , located in Westminster of Co and trading under the symbol ABIO
What is ARCA biopharma, Inc. stock quote today ?
ARCA biopharma, Inc. stock price is $3.31 today.
Is ARCA biopharma, Inc. stock public?
Yes, ARCA biopharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.43M
- Market Capitalization 46.84M
- Employee 4
- CEO Dr. Michael R. Bristow M.D., Ph.D.
- Headquarters Westminster,CO,US
- IPO Date 1997-08-08
-
Website
https://www.arcabio.com 
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
